MCID: HPT023
MIFTS: 89

Hepatocellular Carcinoma

Categories: Genetic diseases, Rare diseases, Liver diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 54 38 12 56 71 29 13 52 14
Liver Cancer 12 71 41 14
Hcc 12 56 71
Adult Primary Hepatocellular Carcinoma 12 69
Primary Malignant Neoplasm of Liver 12 69
Malignant Neoplasm of Liver 12 69
Hepatoblastoma, Somatic 54 13
Primary Liver Cancer 12 50
Liver Neoplasms 42 69
Hepatic Cancer 12 52
Hepatoblastoma 56 69
Liver Neoplasm 12 14
Hepatoma 12 71
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm 12
Rare Tumor of Liver and Intrahepatic Biliary Tract 50
Hepatocellular Carcinoma, Childhood Type, Somatic 54
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 69
Resectable Malignant Neoplasm of the Liver 12
Malignant Neoplasm of Liver Unspecified 12
Primary Malignant Neoplasm of Liver Nos 12
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Hepatocellular Carcinoma, Somatic 54
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 50
Malignant Hepatobiliary Neoplasm 69
Hepatocellular Cancer, Somatic 54
Primary Tumor of the Liver 50
Carcinoma, Hepatocellular 42
Malignant Tumor of Liver 12
Primary Cancer of Liver 50
Primary Liver Carcinoma 50
Hepatocellular Cancer 71
Neoplasm of the Liver 29
Liver Cell Carcinoma 71
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 69
Adult Hepatoma 12
Lcc 71

Characteristics:

Orphanet epidemiological data:

56
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;

OMIM:

54
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

32
hepatocellular carcinoma:
Inheritance somatic mutation heterogeneous autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. primary liver cancer starts in the liver. metastatic liver cancer starts somewhere else and spreads to your liver. risk factors for primary liver cancer include having hepatitis b or c heavy alcohol use having cirrhosis, or scarring of the liver having hemochromatosis, an iron storage disease obesity and diabetes symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. however, you may not have symptoms until the cancer is advanced. this makes it harder to treat. doctors use tests that examine the liver and the blood to diagnose liver cancer. treatment options include surgery, radiation, chemotherapy, or liver transplantation. nih: national cancer institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to colorectal cancer and prostate cancer, and has symptoms including micronodular cirrhosis, subacute progressive viral hepatitis and hepatosplenomegaly. An important gene associated with Hepatocellular Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Development HGF signaling pathway and Endometrial cancer. The drugs Feridex I.V. and Nexavar have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes.

OMIM : 54
Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550)

UniProtKB/Swiss-Prot : 71 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 72 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 398)
id Related Disease Score Top Affiliating Genes
1 colorectal cancer 32.0 APC AXIN1 CASP8 CTNNB1 IGF2R MET
2 prostate cancer 31.7 CASP8 CDKN3 CTNNB1 MET PIK3CA TERT
3 adrenal cortical carcinoma 31.4 CASP8 CTNNB1 MET PIK3CA TERT TP53
4 peritoneal mesothelioma 31.2 CTNNB1 PIK3CA TERT TP53
5 childhood hepatocellular carcinoma 12.3
6 mixed fibrolamellar hepatocellular carcinoma 12.2
7 fibrolamellar carcinoma 12.0
8 adult hepatocellular carcinoma 12.0
9 aflatoxins-related hepatocellular carcinoma 11.8
10 ruijs-aalfs syndrome 11.7
11 gastric cancer, somatic 11.6 AFP APC CTNNB1 MET PIK3CA TP53
12 gallbladder cancer 11.6 AFP CTNNB1 MET PIK3CA TP53 VEGFA
13 gastric fundus cancer 11.6 AFP APC CASP8 CTNNB1 MET PIK3CA
14 skin tag 11.5 AFP APC CTNNB1 HNF1A MET
15 brown-vialetto-van laere syndrome 11.5 AFP CTNNB1 TP53 VEGFA
16 trachea squamous cell carcinoma 11.5 CTNNB1 PIK3CA TP53 VEGFA
17 diabetes mellitus, insulin-dependent, 20 11.5 AFP APC CTNNB1 HNF1A
18 esophagus lymphoma 11.5 CTNNB1 PIK3CA TERT TP53 VEGFA
19 colon signet ring adenocarcinoma 11.5 AFP APC CTNNB1 TP53
20 hartnup disorder 11.5 CASP8 CTNNB1 MET PIK3CA TERT TP53
21 arrhythmogenic right ventricular cardiomyopathy 11.5 APC AXIN1 CTNNB1 TP53
22 exudative vitreoretinopathy 7 11.5 CASP8 CTNNB1 MET PIK3CA TERT TP53
23 glycogen storage disease due to lactate dehydrogenase deficiency 11.4 AXIN1 CASP8 CTNNB1 PDGFRL PIK3CA TP53
24 nail disorder, nonsyndromic congenital, 1 11.4 CTNNB1 TERT TP53 VEGFA
25 spinal cord dermoid cyst 11.4 AXIN1 CTNNB1 TP53
26 split-hand/foot malformation 4 11.4 CTNNB1 PIK3CA TP53
27 enamel hypoplasia cataract hydrocephaly 11.4 AXIN1 CTNNB1 TP53
28 brenner tumor of the vagina 11.4 APC PIK3CA TP53
29 nail disorder, nonsyndromic congenital, 3, 11.4 CTNNB1 PIK3CA TERT TP53 VEGFA
30 brenner tumor of ovary 11.4 APC PIK3CA TP53
31 rectum kaposi's sarcoma 11.4 CTNNB1 PIK3CA TP53
32 dental caries 11.4 PIK3CA TP53 VEGFA
33 ovarian brenner tumor 11.4 MET PIK3CA TP53 VEGFA
34 nasal cavity disease 11.4 PIK3CA TP53 VEGFA
35 glioblastoma 3 11.4 APC AXIN1 CASP8 CTNNB1 TP53
36 maxillary neoplasm 11.4 APC CTNNB1 TP53
37 trachea carcinoma in situ 11.4 MET TP53 VEGFA
38 sparse hair ptosis mental retardation 11.4 TERT TP53 VEGFA
39 mantle cell lymphoma 11.4 CASP8 MET TERT TP53 VEGFA
40 desmoid disease, hereditary 11.4 APC AXIN1 CTNNB1
41 cleft lip palate dysmorphism kumar type 11.4 MET TP53 VEGFA
42 tyrosinemia, type i 11.4
43 hepatitis c virus 11.4
44 differentiating neuroblastoma 11.4 MET PIK3CA TERT
45 rare endometriosis 11.4 CTNNB1 TERT TP53
46 endometriosis of uterus 11.4 CTNNB1 TP53 VEGFA
47 arteritic anterior ischemic optic neuropathy 11.4 CTNNB1 TP53 VEGFA
48 bleeding disorder, platelet-type, 13 11.3 APC CTNNB1 TP53
49 sertoli-leydig cell tumor 11.3 CTNNB1 MET TP53 VEGFA
50 childhood-onset schizophrenia 11.3 CTNNB1 MET

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Symptoms via clinical synopsis from OMIM:

54

Abdomen- Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory- Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer


Clinical features from OMIM:

114550

Human phenotypes related to Hepatocellular Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 hepatocellular carcinoma 32 HP:0001402
2 micronodular cirrhosis 32 HP:0001413
3 subacute progressive viral hepatitis 32 HP:0006572

UMLS symptoms related to Hepatocellular Carcinoma:


hepatosplenomegaly, icterus, abdominal pain, fever, malaise, constipation, diarrhea, dyspepsia, heartburn, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 IGF2R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 IGF2R PEG10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.9 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.9 PEG10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.9 APC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 IGF2R PEG10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.9 PEG10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.9 PEG10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 PIK3CA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.9 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.9 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 APC PIK3CA CTNNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.9 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.9 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.9 APC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.9 IGF2R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.9 IGF2R
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 PEG10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.9 CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 IGF2R PEG10 APC PIK3CA CTNNB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.9 CTNNB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.9 IGF2R CTNNB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.9 APC CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.9 CTNNB1

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 FAH HNF1A IGF2R MET MTUS1 PEG10
2 growth/size/body region MP:0005378 10.43 MET MTUS1 PEG10 PIK3CA STARD13 TERT
3 endocrine/exocrine gland MP:0005379 10.38 APC CASP8 CTNNB1 FAH HNF1A IGF2R
4 homeostasis/metabolism MP:0005376 10.36 TERT TP53 VEGFA AFP APC CASP8
5 mortality/aging MP:0010768 10.34 AFP APC AXIN1 CASP8 CTNNB1 FAH
6 behavior/neurological MP:0005386 10.33 AFP APC AXIN1 CTNNB1 FGL1 HNF1A
7 cardiovascular system MP:0005385 10.32 APC AXIN1 CASP8 CTNNB1 IGF2R MET
8 embryo MP:0005380 10.25 CASP8 CTNNB1 IGF2R MET PEG10 PIK3CA
9 immune system MP:0005387 10.24 APC CASP8 CTNNB1 FAH MET MTUS1
10 digestive/alimentary MP:0005381 10.21 APC AXIN1 CTNNB1 HNF1A MET MTUS1
11 liver/biliary system MP:0005370 10.2 AFP APC CASP8 CTNNB1 FAH FGL1
12 neoplasm MP:0002006 10.15 AFP APC CASP8 CTNNB1 FAH MET
13 craniofacial MP:0005382 10.11 VEGFA APC AXIN1 CTNNB1 IGF2R MET
14 limbs/digits/tail MP:0005371 10.02 APC AXIN1 CTNNB1 IGF2R MET TP53
15 muscle MP:0005369 10.01 MET PIK3CA TP53 VEGFA APC CASP8
16 renal/urinary system MP:0005367 10 FAH HNF1A IGF2R MET MTUS1 TP53
17 no phenotypic analysis MP:0003012 9.87 APC CTNNB1 HNF1A MET PIK3CA TP53
18 reproductive system MP:0005389 9.85 HNF1A IGF2R PIK3CA TERT TP53 VEGFA
19 respiratory system MP:0005388 9.56 AXIN1 CASP8 CTNNB1 IGF2R MET TERT
20 skeleton MP:0005390 9.32 APC AXIN1 CTNNB1 FGL1 HNF1A IGF2R

Drugs & Therapeutics for Hepatocellular Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Feridex I.V. 17 FERUMOXIDES Advanced Magnetics February 1996
2
Nexavar 17 46 SORAFENIB TOSYLATE Bayer/Onyx December 2005

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 551)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2 198153-51-4 5360545
2
Ribavirin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 36791-04-5 37542
3
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 142217-69-4 153941
4
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
5
Carboplatin Approved Phase 4,Phase 2,Phase 3 41575-94-4 10339178 498142 38904
6
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
7
Ethiodized oil Approved Phase 4,Phase 3,Phase 2,Phase 1 8008-53-5
8
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 284461-73-0 216239 406563
9
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
10
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2 525-66-6 4946
11
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
12
Coal tar Approved Phase 4,Phase 3,Phase 2 8007-45-2
13
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
14
Nadolol Approved Phase 4 42200-33-9 39147
15
Pravastatin Approved Phase 4,Phase 3,Phase 2 81093-37-0 54687
16
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
17
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
18
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
19
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
20
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
21
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
23
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
24
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
25
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
26
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
27
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
28
Dalteparin Approved Phase 4,Phase 2,Phase 3 9005-49-6
29
Dipyridamole Approved Phase 4 58-32-2 3108
30
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 772 46507594
31 Nadroparin Approved Phase 4,Phase 2,Phase 3 9041-08-1
32
Warfarin Approved Phase 4 81-81-2 6691 54678486
33
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
34
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
35
Thymalfasin Approved, Investigational Phase 4,Phase 2 62304-98-7
36
Ledipasvir Approved Phase 4,Phase 3 1256388-51-8 67505836
37
Sofosbuvir Approved Phase 4,Phase 3,Phase 2 1190307-88-0 45375808
38
Cefazolin Approved Phase 4 25953-19-9 656510 33255
39
Norepinephrine Approved Phase 4 51-41-2 439260
40
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
41
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
42
Desflurane Approved Phase 4 57041-67-5 42113
43
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
44
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
45
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
46
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
48
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 59-67-6 938
49
Nicotinamide Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 98-92-0 936
50
acetic acid Approved, Nutraceutical Phase 4 64-19-7 176

Interventional clinical trials:

(show top 50) (show all 1591)

id Name Status NCT ID Phase Drugs
1 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
2 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
3 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
4 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
5 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
6 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
7 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
8 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
9 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
10 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
11 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
12 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
13 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
14 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
15 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
16 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
17 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
18 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
19 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
20 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
21 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
22 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
23 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
24 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
25 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
26 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
27 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4 GADOXETIC ACID
28 Drug-eluting Bead in Hepatocellular Carcinoma Completed NCT01332669 Phase 4
29 Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Completed NCT00646100 Phase 4
30 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Completed NCT01600196 Phase 4
31 Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients Completed NCT01098760 Phase 4 Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
32 Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC). Completed NCT01798160 Phase 4
33 Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma Completed NCT00829465 Phase 4 Licartin
34 Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC Completed NCT00375661 Phase 4 interferon-alfa-2b and ribavirin
35 Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) Completed NCT01203787 Phase 4 Sorafenib Standard Dosing Regimen;Sorafenib Ramp-Up Regimen
36 Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion Completed NCT01952353 Phase 4
37 Hepatic Xenetix-CT Perfusion Completed NCT01639703 Phase 4 Xenetix-CT perfusion imaging
38 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma Completed NCT00630084 Phase 4 pegylated interferon alpha 2a and plus ribavirin;pegylated interferon alpha 2a and plus ribavirin
39 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
40 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy Completed NCT01770431 Phase 4 Huaier Granule
41 A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC Completed NCT01263002 Phase 4 clevudine, Adefovir
42 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) Completed NCT00397540 Phase 4
43 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail Completed NCT02961998 Phase 4 Celecoxib;Sorafenib
44 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
45 Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients Completed NCT03007225 Phase 4 Trans-arterial chemoembolization (TACE);TACE with Drug Eluting Beads procedure
46 Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE Completed NCT00936689 Phase 4
47 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
48 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4
49 Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity Completed NCT00957866 Phase 4 Pegylated Interferons (Peg-IFN) and Ribavirin
50 Qidong Hepatitis B Intervention Study Completed NCT00222664 Phase 4

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: carcinoma, hepatocellular

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

id Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 29
2 Neoplasm of the Liver 29

Anatomical Context for Hepatocellular Carcinoma

MalaCards organs/tissues related to Hepatocellular Carcinoma:

39
Liver, Endothelial, T Cells, Testes, Lung, Skin, Bone

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 9481)
id Title Authors Year
1
Expression of microRNA let-7a positively correlates with hepatitis B virus replication in hepatocellular carcinoma tissues. ( 28440732 )
2017
2
SIRT3 functions as a tumor suppressor in hepatocellular carcinoma. ( 28347248 )
2017
3
MicroRNA-185 induces potent autophagy via AKT signaling in hepatocellular carcinoma. ( 28240051 )
2017
4
MicroRNA-144 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by targeting ZFX. ( 28229969 )
2017
5
Downregulation of esophageal cancer-related gene 4 promotes proliferation and migration of hepatocellular carcinoma. ( 28927132 )
2017
6
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. ( 28067792 )
2017
7
MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma. ( 27922690 )
2017
8
Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan. ( 28260989 )
2017
9
Deacetylation of Ku70 by SIRT6 attenuates Bax-mediated apoptosis in hepatocellular carcinoma. ( 28238784 )
2017
10
FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression. ( 28260073 )
2017
11
The Effect of New Therapeutic and Diagnostic Agents on the Prognosis of Hepatocellular Carcinoma in Japan a89 An Analysis of Data from the Kanagawa Cancer Registry ( 28952279 )
2017
12
Downregulation of UBAP2L Inhibits the Epithelial-Mesenchymal Transition via SNAIL1 Regulation in Hepatocellular Carcinoma Cells. ( 28334716 )
2017
13
BCLB, methylated in hepatocellular carcinoma, is a starvation stressA sensor that induces apoptosis and autophagy through theA AMPK-mTOR signaling cascade. ( 28259820 )
2017
14
A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma. ( 28529568 )
2017
15
Long nona89coding RNA AB019562 promotes cell proliferation and metastasis in human hepatocellular carcinoma. ( 28534955 )
2017
16
B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells. ( 28351336 )
2017
17
Intractable Fasting Hypoglycemia as a Manifestation of Hepatocellular Carcinoma. ( 28785493 )
2017
18
TINCR expression is associated with unfavorable prognosis in patients with hepatocellular carcinoma. ( 28546230 )
2017
19
Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. ( 28948495 )
2017
20
Promising significance of the association of miR-204-5p expression with clinicopathological features of hepatocellular carcinoma. ( 28746200 )
2017
21
ARID1A represses hepatocellular carcinoma cell proliferation and migration through lncRNA MVIH. ( 28716731 )
2017
22
Value of Nonrigid Registration of Pre-Procedure MR with Post-Procedure CT After Radiofrequency Ablation for Hepatocellular Carcinoma. ( 28091728 )
2017
23
Immediate early response proteinA 2 regulates hepatocellular carcinoma cell adhesion and motility via integrinA I^1-mediated signaling pathway. ( 27840969 )
2017
24
An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma. ( 28034876 )
2017
25
MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation. ( 27998765 )
2017
26
Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma. ( 27899259 )
2017
27
Polyethylene glycol-poly(I/-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma. ( 28533682 )
2017
28
Long non-coding RNA CASC2 regulates cell biological behaviour through the MAPK signalling pathway in hepatocellular carcinoma. ( 28621238 )
2017
29
Management of hepatocellular carcinoma in thalassemia and importance of the human factor. ( 28085196 )
2017
30
RYBP Expression Is Regulated by KLF4 and Sp1 and Is Related to Hepatocellular Carcinoma Prognosis. ( 28028181 )
2017
31
The overexpression and prognostic role of DCAF13 in hepatocellular carcinoma. ( 28631558 )
2017
32
Fructose-1,6-Bisphosphatase 1 Reduces (18)F FDG Uptake in Hepatocellular Carcinoma. ( 28387640 )
2017
33
Diabetes mellitus increases the risk of intrahepatic recurrence of hepatocellular carcinoma after surgical resection. ( 28085178 )
2017
34
Early-age hepatocellular carcinoma associated with hepatitis B infection in South America. ( 28532694 )
2017
35
Mature Cystic Teratoma With an Element of Hepatocellular Carcinoma in Anterior Mediastinum: Magnetic Resonance-Pathologic Correlation. ( 28914742 )
2017
36
Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades. ( 28534824 )
2017
37
Clinicopathological analysis of concomitant hepatic embryonal rhabdomyosarcoma and hepatocellular carcinoma. ( 28554759 )
2017
38
Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. ( 28860489 )
2017
39
Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population. ( 28147320 )
2017
40
HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma. ( 28153790 )
2017
41
Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular Carcinoma. ( 28951629 )
2017
42
Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma. ( 27993894 )
2017
43
Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect. ( 27742690 )
2017
44
miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1. ( 28342862 )
2017
45
Roles of microRNA-330 and Its Target Gene ING4 in the Development of Aggressive Phenotype in Hepatocellular Carcinoma Cells. ( 28050784 )
2017
46
The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1. ( 28720061 )
2017
47
Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. ( 28218222 )
2017
48
Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma. ( 27879964 )
2017
49
Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline. ( 28422868 )
2017
50
Overexpression of NAD(P)H: Quinone Oxidoreductase 1 Inhibits Hepatocellular Carcinoma Cell Proliferation and Induced Apoptosis by Activating AMPK/PGC-1I+ Pathway. ( 28191864 )
2017